The risk of dialysis access thrombosis is related to the transforming growth factor-β1 production haplotype and is modified by polymorphisms in the plasminogen activator inhibitor-type 1 gene

Blood

Volumn 108, Issue 13, 2006, Pages 4052-4058

  Lazo Langner, Alejandro ^b   Knoll, Greg A ^b   Wells, Philip S ^b   Carson, Nancy ^b   Rodger, Marc A ^a  

^a UNIVERSITY OF OTTAWA   (Canada)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTITHROMBOCYTIC AGENT; CYANOCOBALAMIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FOLIC ACID; MULTIVITAMIN; PLASMINOGEN ACTIVATOR INHIBITOR 1; PYRIDOXINE; TRANSFORMING GROWTH FACTOR BETA1; WARFARIN;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; FEMALE; GENETIC POLYMORPHISM; GENOTYPE; HAPLOTYPE; HEMODIALYSIS; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RISK FACTOR; SURVIVAL; THROMBOSIS; VASCULAR ACCESS;

EID: 33845506607     PISSN: 00064971     EISSN: 00064971     Source Type: Journal    
DOI: 10.1182/blood-2006-06-028902     Document Type: Article

References (44)

1. Schwab SJ. Vascular access for hemodialysis. Kidney Int. 1999;55:2078-2090.
2. Feldman HI, Kobrin S, Wasserstein A. Hemodialysis vascular access morbidity. J Am Soc Nephrol. 1996;7:523-535.
3. Schwab SJ, Oliver MJ, Suhocki P, McCann R. Hemodialysis arteriovenous access: detection of stenosis and response to treatment by vascular access blood flow. Kidney Int. 2001;59:358-362.
4. Stracke S, Konner K, Kostlin I, et al. Increased expression of TGF-β1 and IGF-I in inflammatory stenotic lesions of hemodialysis fistulas. Kidney Int. 2002;61:1011-1019.
5. Ikegaya N, Yamamoto T, Takeshita A, et al. Elevated erythropoietin receptor and transforming growth factor-β1 expression in stenotic arteriovenous fistulae used for hemodialysis. J Am Soc Nephrol. 2000;11:928-935.
6. Rao M, Guo D, Jaber BL, Tighiouart H, Pereira BJG, Balakrishnan VS. Transforming growth factor-β 1 gene polymorphisms and cardiovascular disease in hemodialysis patients. Kidney Int. 2004;66:419-427.
7. August P, Suthanthiran M. Transforming growth factor β and progression of renal disease. Kidney Int. 2003;64:99-104.
8. Awad MR, El Gamel A, Hasleton P, Turner DM, Sinnott PJ, Hutchinson IV. Genotypic variation in the transforming growth factor-β1 gene: association with transforming growth factor-β1 production, fibrotic lung disease, and graft fibrosis after lung transplantation. Transplantation. 1998;66:1014-1020.
9. Perrey C, Pravica V, Sinnott PJ, Hutchinson IV. Genotyping for polymorphisms in interferon-gamma, interleukin-10, transforming growth factor-β1 and tumour necrosis factor-alpha genes: a technical report. Transpl Immunol. 1998;6:193-197.
10. Heine GH, Ulrich C, Sester U, Sester M, Kohler H, Girndt M. Transforming growth factor β1 genotype polymorphisms determine AV fistula patency in hemodialysis patients. Kidney Int. 2003;64:1101-1107.
11. Knoll GA, Wells PS, Young D, et al. Thrombophilia and the risk for hemodialysis vascular access thrombosis. J Am Soc Nephrol. 2005;16:1108-1114.
12. De Taeye B, Gils A, Declerck PJ. The story of the serpin plasminogen activator inhibitor 1: is there any need for another mutant? Thromb Haemost. 2004;92:898-924.
13. Fay WP. Plasminogen activator inhibitor 1, fibrin, and the vascular response to injury. Trends Cardiovasc Med. 2004;14:196-202.
14. Dano K, Behrendt N, Hoyer-Hansen G, et al. Plasminogen activation and cancer. Thromb Haemost. 2005;93:676-681.
15. Jovin IS, Muller-Berghaus G. Interrelationships between the fibrinolytic system and lipoproteins in the pathogenesis of coronary atherosclerosis. Atherosclerosis. 2004;174:225-233.
16. Aucella F, Margaglione M, Vigilante M, et al. PAI-1 4G/5G and ACE I/D gene polymorphisms and the occurrence of myocardial infarction in patients on intermittent dialysis. Nephrol Dial Transplant. 2003;18:1142-1146.
17. Wiklund PG, Nilsson L, Ardnor SN, et al. Plasminogen activator inhibitor-1 4G/5G polymorphism and risk of stroke: replicated findings in two nested case-control studies based on independent cohorts. Stroke. 2005;36:1661-1665.
18. Woodward RN, Finn AV, Dichek DA. Identification of intracellular pathways through which TGF-β1 upregulates PAI-1 expression in endothelial cells. Atherosclerosis. 2006;186:92-100.
19. Mas VR, Fisher RA, Maluf DG, et al. Polymorphisms in cytokines and growth factor genes and their association with acute rejection and recurrence of hepatitis C virus disease in liver transplantation. Clin Genet. 2004;65:191-201.
20. De La Vega FM, Dailey D, Ziegle J, Williams J, Madden D, Gilbert DA. New generation pharmacogenomic tools: a SNP linkage disequilibrium Map, validated SNP assay resource, and high-throughput instrumentation system for large-scale genetic studies. Biotechniques. 2002;32(6 suppl):S48-S54.
21. Liu K, Muse SV. PowerMarker: an integrated analysis environment for genetic marker analysis. Bioinformatics. 2005;21:2128-2129.
22. Wells PS, Anderson JL, Scarvelis DK, Doucette SP, Gagnon F. Factor XIII Val34Leu variant is protective against venous thromboembolism: a HuGE review and meta-analysis. Am J Epidemiol. 2006;164:101-109.
23. Kaplan EL, Meier P. Non-parametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457-481.
24. Khoury MJ, Flanders WD. Nontraditional epidemiologic approaches in the analysis of gene-environment interaction: case-control studies with no controls! Am J Epidemiol. 1996;144:207-213.
25. Yang Q, Khoury MJ, Sun F, Flanders WD. Case-only design to measure gene-gene interaction. Epidemiology. 1999;10:167-170.
26. Gauderman WJ. Sample size requirements for association studies of gene-gene interaction. Am J Epidemiol. 2002;155:478-484.
27. Heine GH, Ulrich C, Kohler H, Girndt M. Is AV fistula patency associated with angiotensin-converting enzyme (ACE) polymorphism and ACE inhibitor intake? Am J Nephrol. 2004;24:461-468.
28. Akman B, Afsar B, Atac FB, et al. Predictors of vascular access thrombosis among patients on the cadaveric renal transplantation waiting list. Transplant Proc. 2006;38:413-415.
29. Sands JJ, Nudo SA, Moore KD, Ortel TL. Antibodies to prothrombin, factor V, and β2-glycoprotein I and vascular access thrombosis. ASAIO J. 2001;47:507-510.
30. Stouffer GA, Owens GK. Angiotensin II-induced mitogenesis of spontaneously hypertensive rat-derived cultured smooth muscle cells is dependent on autocrine production of transforming growth factor-β. Circ Res. 1992;70:820-828.
31. Battegay EJ, Raines EW, Seifert RA, Bowen-Pope DF, Ross R. TGF-β induces bimodal proliferation of connective tissue cells via complex control of an autocrine PDGF loop. Cell. 1990;63:515-524.
32. Grainger DJ, Kemp PR, Witchell CM, Weissberg PL, Metcalfe JC. Transforming growth factor β decreases the rate of proliferation of rat vascular smooth muscle cells by extending the G2 phase of the cell cycle and delays the rise in cyclic AMP before entry into M phase. Biochem J. 1994;299(pt 1):227-235.
33. Kojima S, Harpel PC, Rifkin DB. Lipoprotein (a) inhibits the generation of transforming growth factor β: an endogenous inhibitor of smooth muscle cell migration. J Cell Biol. 1991;113:1439-1445.
34. Grainger DJ. Transforming growth factor β and atherosclerosis: so far, so good for the protective cytokine hypothesis. Arterioscler Thromb Vasc Biol. 2004;24:399-404.
35. Fujisawa M, Haramaki R, Miyazaki H, Imaizumi T, Okuda S. Role of lipoprotein (a) and TGF-β1 in atherosclerosis of hemodialysis patients. J Am Soc Nephrol. 2000;11:1889-1895.
36. Stefoni S, Cianciolo G, Donati G, et al. Low TGF-β1 serum levels are a risk factor for atherosclerosis disease in ESRD patients. Kidney Int. 2002;61:324-335.
37. Lawn RM, Pearle AD, Kunz LL, et al. Feedback mechanism of focal vascular lesion formation in transgenic apolipoprotein(a) mice. J Biol Chem. 1996;271:31367-31371.
38. Borkowski P, Robinson MJ, Kusiak JW, Borkowski A, Brathwaite C, Mergner WJ. Studies on TGF-β 1 gene expression in the intima of the human aorta in regions with high and low probability of developing atherosclerotic lesions. Mod Pathol. 1995;8:478-482.
39. Sho E, Nanjo H, Sho M, et al. Arterial enlargement, tortuosity, and intimal thickening in response to sequential exposure to high and low wall shear stress. J Vasc Surg. 2004;39:601-612.
40. Ene-Iordache B, Mosconi L, Remuzzi G, Remuzzi A. Computational fluid dynamics of a vascular access case for hemodialysis. J Biomech Eng. 2001;123:284-292.
41. Corpataux JM, Haesler E, Silacci P, Ris HB, Hayoz D. Low-pressure environment and remodelling of the forearm vein in Brescia-Cimino haemodialysis access. Nephrol Dial Transplant. 2002;17:1057-1062.
42. Samijo SK, Barkhuysen R, Willigers JM, et al. Wall shear stress assessment in the common carotid artery of end-stage renal failure patients. Nephron. 2002;92:557-563.
43. Ohno M, Cooke JP, Dzau VJ, Gibbons GH. Fluid shear stress induces endothelial transforming growth factor β-1 transcription and production: modulation by potassium channel blockade. J Clin Invest. 1995;95:1363-1369.
44. Lazo-Langner A, Knoll GA, Wells PS, Pilkey RM, Carson N, Rodger MA. The risk of dialysis access thrombosis is related to polymorphisms in the transforming growth factor-beta1 and plasminogen activator inhibitor-type 1 genes. Blood. 2005;106:466a-467a. Abstract 1631.